Marker Therapeutics GAAP EPS of -$1.19, revenue of $6.59M
Source: SeekingAlpha
2025-03-31 08:47:53 ET
More on Marker Therapeutics
- Seeking Alpha’s Quant Rating on Marker Therapeutics
- Historical earnings data for Marker Therapeutics
- Financial information for Marker Therapeutics
Read the full article on Seeking Alpha
For further details see:
Marker Therapeutics GAAP EPS of -$1.19, revenue of $6.59M
Marker Therapeutics Inc.
NASDAQ: MRKR
MRKR Trading
0.74% G/L:
$1.37 Last:
71,716 Volume:
$1.38 Open:
MRKR Latest News
February 18, 2026 08:00:00 am
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
January 26, 2026 07:00:00 am
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics' MAR-T Cell Technology
January 05, 2026 07:00:00 am
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
November 14, 2025 07:00:00 am
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
MRKR Stock Data
$25,759,981
15,372,623
3.36%
21
N/A
Biotechnology & Life Sciences
Healthcare
US
Houston
